Vermorken, J. B., & Krauß, J. (2014). Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: Results of the randomized phase I/II ADVANTAGE trial (phase II part). Annals of oncology, 25(3), . https://doi.org/10.1093/annonc/mdu003
Chicago-Zitierstil (17. Ausg.)Vermorken, Jan B., und Jürgen Krauß. "Cisplatin, 5-fluorouracil, and Cetuximab (PFE) with or Without Cilengitide in Recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck: Results of the Randomized Phase I/II ADVANTAGE Trial (phase II Part)." Annals of Oncology 25, no. 3 (2014). https://doi.org/10.1093/annonc/mdu003.
MLA-Zitierstil (9. Ausg.)Vermorken, Jan B., und Jürgen Krauß. "Cisplatin, 5-fluorouracil, and Cetuximab (PFE) with or Without Cilengitide in Recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck: Results of the Randomized Phase I/II ADVANTAGE Trial (phase II Part)." Annals of Oncology, vol. 25, no. 3, 2014, https://doi.org/10.1093/annonc/mdu003.